Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report

Checkpoint inhibitors (CIs) are now standard of care for late-stage non-small-cell lung cancer (NSCLC); however, only a minority of patients treated with a CI show clinical benefit compared to platinum-based chemotherapy alone, regardless of programmed cell death ligand 1 (PD-L1) expression levels....

Descripción completa

Detalles Bibliográficos
Autores principales: Gollard, Russell, Arana, Bill, Kaltenbrun, Erin, Tebbey, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294266/
https://www.ncbi.nlm.nih.gov/pubmed/37384204
http://dx.doi.org/10.1159/000530132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294266/
https://www.ncbi.nlm.nih.gov/pubmed/37384204
http://dx.doi.org/10.1159/000530132

Ejemplares similares